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Reducing olanzapine-induced weight gain side-effect by using betahistine: a 
study in the rat model 
Abstract 
Olanzapine is effective at treating multiple domains of schizophrenia symptoms. However, it induces 
serious metabolic side effects. Antipsychotic drug’s antagonistic affinity to histamine H1 receptors has 
been identified as a main contributor for weight gain/obesity side effects. This study therefore 
investigated whether a combined treatment of betahistine (a H1 receptor agonist and H3 receptor 
antagonist) could reduce the body weight/obesity induced by olanzapine. Female Sprague Dawley rats 
were treated orally with olanzapine (1 mg/kg, t.i.d.) and/or betahistine (2.67 mg/kg, t.i.d.), or vehicle for 
two weeks. Rats treated with olanzapine exhibited significant body weight gain and increased food intake. 
Co-treatment of olanzapine with betahistine significantly prevented (-45%) weight gain and reduced 
feeding efficiency compared to sole olanzapine treatment. Betahistine treatment alone had no effect on 
weight gain and food intake. Olanzapine reduced locomotor activity, but not betahistine. These findings 
demonstrate that olanzapine-induced body weight gain can partially be reduced by co-treatment with 
betahistine. Betahistine has H3 receptor antagonistic effects to increase histamine release, which may 
augment its direct agonistic effects on H1 receptors. These findings have important implications for 
clinical trials using betahistine to control antipsychotic-induced obesity side effects. 
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Olanzapine is effective at treating multiple domains of schizophrenia symptoms. 
However, it induces serious metabolic side-effects. Antipsychotic drug’s antagonistic 
affinity to histamine H1 receptors has been identified as a main contributor for weight 
gain/obesity side-effects. This study therefore investigated whether a combined 
treatment of betahistine (a H1 receptor agonist and H3 receptor antagonist) could reduce 
the body weight/obesity induced by olanzapine. Female Sprague Dawley rats were 
treated orally with olanzapine (1 mg/kg, t.i.d) and/or betahistine (2.67 mg/kg, t.i.d.), or 
vehicle for two weeks. Rats treated with olanzapine exhibited significant body weight 
gain and increased food intake. Co-treatment of olanzapine with betahistine 
significantly prevented (-45%) weight gain and reduced feeding efficiency compared to 
sole olanzapine treatment. Betahistine treatment alone had no effect on weight gain and 
food intake. Olanzapine reduced locomotor activity, but not betahistine. These findings 
demonstrate that olanzapine-induced body weight gain can partially be reduced by co-
treatment with betahistine. Betahistine has H3 receptor antagonistic effects to increase 
histamine release, which may augment its direct agonistic effects on H1 receptors. These 
findings have important implications for clinical trials using betahistine to control 
antipsychotic-induced obesity side-effects. 
Key words: Antipsychotic; olanzapine; betahistine; weight gain; food intake; locomotor 
activity 





Second generation antipsychotic drugs (SGAs) currently form the first line of treatment 
for schizophrenia (Leucht et al., 2009; Komossa et al., 2010c), and have also been 
widely used to control other mental disorders, such as bipolar disorder, dementia, major 
depression, and Tourette’s syndrome (Depping et al., 2010; Komossa et al., 2010a; 
Komossa et al., 2010b; Zuddas et al., 2011). Among them, olanzapine has proven 
efficacy to treat schizophrenia with enhanced tolerability compared to older first 
generation antipsychotics (Lieberman et al., 2005; Balu et al., 2008). Its most serious 
side-effects, however, are substantial weight gain, increased adiposity and other 
metabolic disorders including hyperlipidemia, hyperglycemia and type II diabetes 
mellitus (Nasrallah, 2008; Patel et al., 2009; Komossa et al., 2010c; Correll et al., 2011; 
Osuntokun et al., 2011).  The recent CAFE (Comparison of Atypicals for First-Episode 
Psychosis) study reported that after 12 weeks of treatment, significant weight gain (≥ 
7% body weight) occurred in a large number of schizophrenia patients treated with 
olanzapine (59.8%), compared to risperidone (32.5%) and quetiapine (29.2%). 
Furthermore, the same investigators found that after 52 weeks of treatment, 80% of 
olanzapine-treated patients gained ≥ 7% body weight, compared to 57.6% risperidone 
and 50% quetiapine-treated patients (Patel et al., 2009). Metabolic dysfunction is a 
significant issue that needs to be addressed in both scientific and clinical research as it 




may lead to further complications such as cardiovascular disease, non-compliance with 
medication and premature death (by 20-30 years) (Haupt et al., 2005; Stahl et al., 2009). 
 
SGAs have binding affinities for various neurotransmitter receptors, such as dopamine 
D2, serotonin 5HT2A and 5HT2C, adrenergic α1-2, muscarinic M1 and M3 and histamine H1 
receptors (Nasrallah, 2008). Accumulated evidence revealed that antagonistic properties 
of H1, 5HT2C and muscarinic receptors are involved in antipsychotic-induced weight 
gain/obesity (Kroeze et al., 2003; Matsui-Sakata et al., 2005; Kirk et al., 2009; Reynolds 
and Kirk, 2010; Weston-Green et al., 2012). In particular, H1 receptor antagonism has 
been identified as the main contributor to olanzapine/clozapine-induced body weight 
gain/obesity side-effects  (Matsui-Sakata et al., 2005; Correll, 2008; Lian et al., 2010). 
A recent study in a rat model showed that short (1 week) and long (12 weeks) term 
treatment of olanzapine significantly reduced H1 receptor mRNA expression in the 
hypothalamic arcuate nucleus (Arc) and ventromedial hypothalamic nucleus (VMH) 
(Han et al., 2008). It is interesting that H1 receptor mRNA expression in the Arc showed 
a significant negative correlation with food intake and fat pad mass (Han et al., 2008). It 
is reported that olanzapine can directly modulate histaminergic neurotransmission, 
which is correlated with the regulation of feeding behaviour of rats (Davoodi et al., 
2008). Kim and colleagues (2007) found that olanzapine and clozapine activate 




hypothalamic AMPK (5' adenosine monophosphate-activated protein kinase) via H1 
receptors to increase food intake and body weight gain (Kim et al., 2007).   
 
The key issue is how to control the antipsychotic-induced body weight gain/obesity 
side-effect. Since the antagonistic affinity of antipsychotics to H1 receptors is the major 
contributor to the weight gain/obesity side-effect, it would be reasonable to combat this 
side-effect using a H1 receptor agonist. In addition, the histamine H3 receptor can act as 
an histamine autoreceptor and is implicated in the control of food intake via regulation 
of histamine release (Deng et al., 2010). Therefore, an agent with the properties of both 
a H1 receptor agonist and H3 receptor antagonist would be a good candidate drug to 
reduce antipsychotic-induced weight gain/obesity. Betahistine is a structural analogue 
of histamine and has both H1-agonistic and H3-antagonistic activity in the brain (Fossati 
et al., 2001; Barak, 2008), therefore has a potential for weight management. Importantly, 
betahistine has a very high safety profile, having been prescribed to over 130 million 
patients for the treatment of vestibular disorders since its registration in 1968, with a 
remarkably low rate (~1:100000) of reported adverse drug reaction (Jeck-Thole and 
Wagner, 2006). Therefore, we investigated the effects of betahistine on attenuating the 
body weight gain side-effect induced by olanzapine in a well-established animal model 
(Huang et al., 2006; Han et al., 2008; Weston-Green et al., 2011).   
 




Materials and Methods  
Animals and Housing  
Forty-eight female Sprague–Dawley rats (201-225 g) were obtained from the Animal 
Resources Centre (Perth, WA, Australia). Rats were housed in pairs for 1 week prior to 
the start of the studies for their adaptation to the new environment, and then housed in 
individual cages under environmentally controlled conditions (22°C, light cycle from 
07:00 to 19:00 and dark cycle from 19:00 to 07:00). They were allowed ad-libitum 
access to water and standard laboratory chow diet (3.9 kcal/g; 10% fat, 74% 
carbohydrate and 16% protein) throughout the whole experiment. All experimental 
procedures were approved by the Animal Ethics Committee, University of Wollongong, 
Australia, and complied with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes (2004).  
 
Drug Treatment 
Prior to drug treatment, rats were trained to self-administer a sweet cookie dough pellet 
(0.3 g) without drugs twice per day for one week. Rats were randomly assigned to one 
of following treatments (n=12/group) for two weeks: (1) olanzapine only (1 mg/kg, t.i.d.; 
Eli Lilly, USA) treatment, (2) betahistine only (2.67 mg/kg, t.i.d.; Manus Aktteva, India) 
treatment, (3) combined olanzapine and betahistine (O+B) treatment, or (4) control 
(vehicle). The pellets with drugs were made prior to administration by mixing droplets 




of water with cookie dough powder (containing 30.9% cornstarch, 30.9% sucrose, 6.3% 
gelatine, 15.5% casein, 6.4% fibre, 8.4% minerals, and 1.6% vitamins) (Deng et al., 
2007; Han et al., 2008; Weston-Green et al., 2011). Controls received an equivalent 
pellet without the drug. Rats were observed during treatment administration to ensure 
complete consumption of the medication pellet. In the rat, the half-life of olanzapine is 
2.5 hours in the plasma and 5.1 hours in the brain, however levels are still high after 8 
hours (Aravagiri et al., 1999), comparing to the half-life of 24.2 hours in the plasma and 
72 hours in the brain of humans (Tauscher et al., 2002). Therefore, in the present study 
rats were administered olanzapine three times/day to ensure a consistently high 
concentrations to better mirror the human scenario of oral administration once per day. 
Body weight, food intake and water intake of rats were measured once every two days.  
 
Open Field Test 
An open field test was performed on day 12 of drug treatment in order to determine 
whether olanzapine and/or betahistine could influence the locomotor activity of rats. A 
rat was placed in the centre of a black rectangular arena (60 × 60 cm2, 40 cm high) that 
was exposed to an average lighting of 25 lux. A video camera was used to record the 
behaviour of the rats for 30 minutes from the top of the arena. The locomotor activity of 
the rats was analysed using EthoVision Color-Pro software (Noldus Information 
Technology, Wageningen, the Netherlands) (du Bois et al., 2008; Weston-Green et al., 




2011). The distance moved (cm) and velocity (cm/s) were measured. In 10 rats (one 
from control, five from olanzapine only and four from O+B groups), behavioural data 
was not recorded due to video camera failure.  
 
Adiposity Measurements  
Following two weeks treatment, all rats were sacrificed by carbon dioxide asphyxiation 
after 24 hours from the last drug treatment. Post-mortem white adipose tissue (WAT) 
including perirenal, periovary and inguinal fat, as well as sub-scapular brown adipose 
tissue (BAT) were dissected and individually weighed (g) (Olds and Olds, 1979).  
 
Statistical Analysis  
Statistical analysis was performed using SPSS (Windows version 17.0, SPSS Inc., 
Chicago). The Kolmogorov-Smirnov test was used to examine the distribution of data 
from all experiments. Two–way ANOVAs (OLANZAPINE × BETAHISTINE) were 
used to examine behaviour and fat mass data. Three-way repeated ANOVAs 
(OLANZAPINE × BETAHISTINE × TIME as repeated measures) were applied to 
examine accumulated weight gain, food and water intake data. Multiple comparisons 
were performed using post-hoc Dunnett-T tests. Pearson’s or Spearman’s correlation 
tests were used to assess the relationships among these measurements. All data were 
expressed as mean ± SEM, and statistical significance was accepted when p<0.05.  







Body Weight Gain  
Three-way repeated ANOVAs (OLANZAPINE × BETAHISTINE × TIME as repeated 
measures) showed significant main effects of TIME (F7,308=145.68, p<0.001), and 
OLANZAPINE factors (F1,44=31.89, p<0.001), but no effect of the BETAHISTINE 
factor (F1,44=3.17, p>0.05) on accumulated body weight gain (Figure 1A). There were 
significant interactions between the OLANZAPINE factor and TIME (F7,308=19.49, 
p<0.001), between the OLANZAPINE and BETAHISTINE factors (F1,44=3.96, 
p=0.053), as well as among all three factors (F7,308=2.99, p<0.01). Post-hoc tests 
showed that body weight gain during the two weeks period was significantly greater in 
the olanzapine only group (p<0.01) compared to controls from day 4 (Figure 1A). 
Further analyses revealed that olanzapine treatment significantly increased body weight 
gain, occurring after four days of treatment with olanzapine and lasting for the entire 
treatment period (all p<0.01). There was a significant increase in total body weight gain 
following olanzapine treatment compared to control (p<0.01) (Table 1). Olanzapine 
plus betahistine (O+B) co-treatment groups had significantly lower body weight gain 
than the sole olanzapine group after two weeks treatment (p<0.05) (Figure 1A, Table 1). 
However, no significant difference was demonstrated between the controls and sole 




betahistine treated rats (Figure 1A, Table 1). Therefore, co-treatment with betahistine 
was effective at reducing the body weight gain side-effect induced by olanzapine. 
 
Food Intake and Feeding Efficiency 
There were significant main effects of the OLANZAPINE factor (F1,42=22.67, p<0.001) 
and TIME (F6,252=4106.67, p<0.001), as well as significant interactions between TIME 
and the OLANZAPINE factors (F6,252=21.15, p<0.001), and between TIME and the 
BETAHISTINE  factors (F6,252=2.59, p<0.05) (Figure 1B). Post-hoc analysis revealed 
that the accumulated food intake of rats significantly increased in the olanzapine only 
group (+15%; p<0.01) compared to controls from day 4 (Figure 1B). Further analysis 
indicated significantly greater accumulated food intake after four days of olanzapine 
only treatment compared to controls (p<0.05). There were significant effects of the 
OLANZAPINE factor (F1,42=25.38, p<0.001) and interaction between the 
OLANZAPINE and BETAHISTINE factors (F1,42=8.77, p<0.01) on feeding efficiency 
(accumulated body weight gain/accumulated food intake) (Figure 1C). Compared to the 
control group, feeding efficiency was significantly increased in the olanzapine treated 
group (p<0.01) and O+B co-treatment group (p<0.05), but not the betahistine treatment 
group (p>0.05) (Figure 1C). It is important that, compared to the sole olanzapine 
treatment group, O+B co-treatment significantly reduced feeding efficiency (-31%; 




p<0.05). Therefore, co-treatment with betahistine was able to prevent the increasing 
feeding efficiency caused by olanzapine treatment. 
 
Fat Deposits 
There were significant effects of the OLANZAPINE factor on the perirenal (F1,44=8.50, 
p<0.01), periovary (F1,44=6.29, p<0.05), inguinal (F1,44=17.48, p<0.001) fat mass, and 
total white fat mass (F1,44=13.38, p=0.001), but no difference was found in sub-scapular 
brown fat mass. Post-hoc analysis revealed a significantly higher inguinal fat mass 
following sole olanzapine treatment (p<0.05) and O+B co-treatment (p<0.05) compared 
to control (Table 1). A significant difference in inguinal fat mass was also found 
between the co-treatment group and betahistine only treated rats (p<0.01). The 
olanzapine group had more total white fat mass than the control group (p=0.058). 
However, the O+B co-treatment group showed less periovary fat and intra-abdominal 
fat than the olanzapine group, but not significant (p>0.05, Table 1).  
 
Water Intake 
There was a significant main effect of TIME (F6,264=1415.89, p<0.001), but not the 
OLANZAPINE factor (F1,44=0.19, p>0.05) and BETAHISTINE factor (F1,44=0.56, 
p>0.05). There was also no interaction between the OLANZAPINE and 
BETAHISTINE factors (F1,44=1.55, p>0.05), or among all three factors (F6,264=1415.89, 




p>0.05) (Figure 1D ) (Table 1). Therefore, both olanzapine and betahistine had no effect 
on water intake. 
 
Locomotor Activity 
There was a significant effect of the OLANZAPINE factor on distance moved 
(F1,34=23.28, p<0.001), but no effect of the BETAHISTINE factor (F1,34=0.06, p>0.05), 
and also no significant interaction between the two factors on distance moved 
(F1,34=3.64, p>0.05) (Figure 2). Post-hoc analysis showed a significant decrease in the 
distance moved in the O+B co-treatment group (p<0.01) and a tendency for a decrease 
in the olanzapine treatment (p=0.067) compared to the control (Figure 2B). In terms of 
velocity, a significant effect was found only in the OLANZAPINE factor (F1,34=26.03, 
p<0.001). Compared to the control, the rats with O+B co-treatment (p<0.01) and sole 
olanzapine treatment (p<0.05) had a significantly lower velocity (Figure 2C). However, 
there was no significant difference between the O+B and olanzapine treatment in both 
distance moved and velocity (p>0.05). Betahistine treatment had no effect on both 
distance moved and velocity (p<0.05).   
 
Correlations among body weight, food intake, fat and behavior data 
There were highly significant correlations between total body weight gain and total food 
intake (r=0.702, p<0.01, Figure 3A) and feeding efficiency (r=0.948, p<0.01, Figure 
3B). Furthermore, total body weight gain was also significantly correlated with intra-




abdominal (r=0.319, p<0.05) and total fat mass (r=0.329, p<0.05) (Figure 3C and D). 
Furthermore, total distance moved was negatively correlated with total body weight 
gain (r=-0.360, p<0.05), and total white fat mass (r=-0.346, p<0.05). Finally, velocity 
was negatively correlated with total body weight gain (r=-0.383, p<0.05).   
 
Discussion 
This was the first study in an animal model to detect the effect of betahistine on 
reducing the body weight gain side-effect caused by olanzapine through a combination 
therapy. A small clinical trial had shown previously that schizophrenia patients co-
administered with olanzapine (10 mg/day) and betahistine (48 mg, t.i.d.) for six weeks 
had no significant weight gain; unfortunately this trial had a very small sample size 
(n=3) and no placebo controls (Poyurovsky et al., 2005). In a well-established 
olanzapine-induced weight gain/obesity rat model, we showed that a combined 
treatment of betahistine and olanzapine reduced weight gain by about 45% compared to 
sole olanzapine treatment, but still had larger body weight gain compared to the placebo 
control. This finding suggests that betahistine co-treatment can only partially reduce 
olanzapine-induced weight gain. There was no difference in body and femur length 
between the groups (Table 1), which indicates that none of the treatments influence 
animal growth. 
 




The animal model of olanzapine-induced weight gain has been well established and 
validated in female rats (Goudie et al., 2002; Fell et al., 2004; Huang et al., 2006; Han et 
al., 2008; Weston-Green et al., 2011), however it can only be modelled in male rats 
under certain conditions, ie. feeding with high carbohydrate (54%)-medium fat (31%)-
low protein (14%) diets (Minet-Ringuet et al., 2006; Shobo et al., 2010). It is interesting 
that the sensitivity of female rats to weight gain side-effect over males is also a common 
observation in the clinic, where female patients have a much higher risk for weight gain 
side-effects weight gain associated with atypical antipsychotics (Weston-Green et al., 
2010). In the present study, the co-treatment group showed a trend for less weight gain 
after 4 days treatment that became significant from day 10 of treatment. This result is 
consistent with the time trend of the small human trial in schizophrenia subjects where 
combined betahistine and olanzapine treatment stopped weight gain after two weeks 
therapy (Poyurovsky et al., 2005). Similar to the body weight gain data, the food intake 
and feeding efficiency of the co-treatment group in the present study was higher than 
the control group, but lower than the olanzapine group. These results suggest that the 
ability of betahistine to decrease olanzapine-induced body weight gain is at least 
partially due to reducing food intake, particularly feeding efficiency. 
 
It is interesting that sole betahistine administration showed no effect on body weight 
and food intake in rats during the two weeks’ experiment. Two acute studies have 




shown that betahistine is effective at reducing food intake for up to 24 hours in rats and 
goats (Rossi et al., 1999; Szelag et al., 2001), however there is no report to investigate 
the long-term effects of betahistine on body weight gain in an animal model. On the 
other hand, several studies have tested betahistine’s anti-obesity effects in humans, but 
the results were not consistent (Barak, 2008; Barak et al., 2008; Ali et al., 2010). In a 
randomized, double-blind, placebo-controlled trial in 20 obese subjects, those treated 
with 16 mg betahistine (b.i.d) for 28 days had reduced fat/protein intake and a 1.1% 
weight loss, compared to 0.6% weight gain in the placebo group (Barak, 2008). In a 
following trial for 12 weeks treatment with betahistine (16-48 mg/day) in 281 adults, 
weight loss was observed in a sub-group of non-Hispanic women ≤ 50 years old, 
although no significant weight loss in over-all comparison with the placebo (Barak et al., 
2008). A recent acute study also showed that betahistine did not affect food intake and 
appetite in obese women after 24 hours treatment (Ali et al., 2010). Possibly, a chronic 
treatment is important for betahistine to affect food intake, or betahistine may be a more 
effective treatment under the conditions of antipsychotic (H1 antagonist)-induced 
obesity. 
 
In this experiment, the sole olanzapine group had more white fat mass than the control 
and sole betahistine groups, which was consistent with previous studies (Fell et al., 
2004; Cooper et al., 2005; Weston-Green et al., 2011). The co-treatment group showed 




a slight decrease in total white fat, which suggests a possible effect of betahistine on 
white fat. This study showed an effect of olanzapine but not betahistine on reducing 
activity. Previous studies revealed a similar result of decreased locomotor activity in 
rats treated with olanzapine and have suggested that olanzapine-induced weight 
gain/obesity is partially attributable to a decrease in energy expenditure (Arjona et al., 
2004; Chintoh et al., 2008; Weston-Green et al., 2011). In fact, treatment of 
schizophrenia patients with olanzapine can lead to less vigorous physical exercise 
(Suzanne et al., 2007; Treuer et al., 2009), and affect energy expenditure (Allison et al., 
1999), contributing to a high risk of body weight gain/obesity side-effect (Green et al., 
2000). Differing to olanzapine, one study found that ziprasidone reduced only 
locomotor activity but did not induce any weight gain (Fell et al., 2007). An early rat 
study revealed that betahistine treatment increased the locomotor activity of rats only at 
very high dose (25 mg/kg, i.p. injection) but not at lower doses (1, 5, 10 mg/kg, i.p. 
injection) (Alvarez et al., 1993)., Under the condition of our experiment, the results 
showed that betahistidine could not improve olanzapine-induced hypolocomotor 
activity in rats.  
 
According to dosage translation between species based on body surface area (Reagan-
Shaw et al., 2007), 1 mg/kg olanzapine in rats is equivalent to ~10 mg in humans (60kg 
body weight), and 2.67 mg/kg betahistine in rats to ~26 mg in humans; both are among 




the recommended doses in the clinic. The olanzapine dosage used in this study has a 
clinically comparable dopamine D2 receptor occupancy (of approximately 70–80%) 
(Kapur et al., 2003), and can increase body weight in female rats (Weston-Green et al., 
2011). The dosage of betahistine is effective at reducing food intake during acute 
treatment in rats (Szelag et al., 2001), but the chronic effect is unknown.  
 
Recent evidence indicates that the binding affinities of olanzapine/clozapine to various 
neurotransmitter receptors such as 5HT2C and M3, but particularly histamine H1 
receptors, correlate with the weight gain/obesity side-effect (Kroeze et al., 2003; 
Matsui-Sakata et al., 2005; Kirk et al., 2009; Reynolds and Kirk, 2010; Weston-Green 
et al., 2012). Although over dozen of drugs (such as metformin, d-fenfluramine, 
topiramate) have been trialled with some success in partly ameliorating antipsychotic-
induced weight gain in both animal models and humans (Maayan et al., 2010), none of 
them are based on the findings of H1 receptors as a main contributor of antipsychotic-
induced weight gain/obesity. Betahistine is the first drug to target histamine receptors as 
an anti-obesity approach to antipsychotic-induced weight gain. As a H1 receptor agonist 
and H3 receptor antagonist, betahistine may reduce olanzapine-induced body weight 
gain/obesity through both the H1 and H3 receptors (Figure 4). Under normal conditions, 
histamine may activate H1 receptors on hypothalamic neurons, leading to a decrease in 
food intake. However, olanzapine blocks histamine H1 receptors on hypothalamic 




neurons causing an increase in food intake (Figure 4A). Since olanzapine has a low 
affinity to H3 autoreceptors, it may have little effect on H3 regulation of histamine 
release. Under the co-treatment of betahistine and olanzapine (Figure 4B), betahistine 
(as a H1 agonist) can directly activate H1 receptors that may compete and decrease 
olanzapine’s H1 antagonist effect. Furthermore, as a H3 receptor antagonist, betahistine 
increases histamine release by blocking presynaptic H3 autoreceptors, which may 
augment its direct agonistic effects on H1 receptors (Figure 4B). Therefore, betahistine 
may reduce food intake and weight gain caused by olanzapine treatment through 
improving H1 neurotransmission. 
 
In conclusion, this study has shown that co-treatment of betahistine with olanzapine can 
partially reduce the olanzapine-induced weight gain side-effect through decreased 
feeding efficiency and food intake. It is worth noting that only a single dose of 
betahistine was used in this study, therefore further studies are required to test whether 
co-treatment with higher dosages of betahistine has better outcomes in relation to 
reducing olanzapine-induced weight gain side-effects. These findings support a 
recommendation for co-administration of betahistidine and olanzapine in a large-scale 
clinical trial and an extension of this co-treatment approach to other antipsychotics, such 
as clozapine and quetiapine to control their weight gain/obesity side-effects.  
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Figure 1 Cumulative body weight gain (A), food intake (B), feeding efficiency (C) 
and water intake (D) in female Sprague Dawley rats treated with olanzapine (1 mg/kg, 
t.i.d.; n=12; ), betahistine (2.67 mg/kg, t.i.d.; n=12), co-treatment (O+B; n=12) or 
control (vehicle; n=12) for 14 days. (▲: olanzapine, x: betahistine, ■: O+B co-treatment,  
●: control). * p<0.05, **p<0.01 vs. control, #p<0.05 vs. olanzapine. 
 





Figure 2 (A) Examples of locomotor activity from rats treated with olanzapine (n=7), 
betahistine (n=12), co-treatment (O+B; n=9) or control (vehicle; n=11). Locomotor 
activity in the open field test was traced using the Ethovision software. (B) Distance 
moved and (C) velocity in the open field test. * p<0.05, **p<0.01 vs. control, 
 






Figure 3 The correlations between total body weight gain (g) and A: total food intake 
(g), B: feeding efficiency, C: intra-abdominal fat mass (g), D: white fat mass (g). 
 






Figure 4 (A) The possible mechanisms of olanzapine-induced weight gain through 
regulation of food intake by blocking histamine H1 receptors; (B) The proposed 
mechanisms of betahistine co-treatment for reducing olanzapine-induced body weight 
gain through its antagonistic action on H3 receptors and agonistic actions on H1 
receptors. 
